Supplementary Materials

The PDF file includes:

  • Patient details: Tumor burden, bridging chemotherapy, and toxicity management information.
  • Fig. S1. OX40L abundance on different types of cells.
  • Fig. S2. Profile of indicated small molecular inhibitors targeting ERK1/2, IKK, and PI3K/AKT.
  • Fig. S3. Small molecular inhibitors targeting ERK1/2, IKK, and PI3K/AKT inhibited the proliferation of CAR-T cells.
  • Fig. S4. Proliferation of 20BBZ-OX40 CAR-T cells.
  • Fig. S5. Proliferation of 20BBOXZ, 20OXBBZ, and 20BBZ-OX40 CAR-T cells.
  • Fig. S6. Proliferation of 20Z, 20Z-OX40, and 20BBZ CAR-T cells.
  • Fig. S7. Proliferation and cytotoxic ability of 19BBZ and 19BBZ-OX40 CAR-T cells.
  • Fig. S8. Proliferation of 1928Z and1928Z-OX40 CAR-T cells.
  • Fig. S9. 20BBZ-OX40 CAR-T cells are less apoptotic than 20BBZ CAR-T cells.
  • Fig. S10. T cell effector and memory subtype analysis of 20BBZ and 20BBZ-OX40 CAR-T cells.
  • Fig. S11. CD4+ and CD8+ T cell subtype analysis of 20BBZ and 20BBZ-OX40 CAR-T cells.
  • Fig. S12. Cytotoxicity of 20BBZ-OX40 CAR-T cells.
  • Fig. S13. Cytokine release from 20BBZ and 20BBZ-OX40 CAR-T cells.
  • Fig. S14. Characterization of the clinical efficacy profile of 20BBZ-OX40 CAR-T in patients.
  • Fig. S15. Immunoglobulin profile after 20BBZ-OX40 CAR-T cell infusion.
  • Table S1. Amino acid sequences of 20BBZ and 20BBZ-OX40.
  • Table S2. CAR-T cell characteristics before patient infusion.

[Download PDF]

Other Supplementary Material for this manuscript includes the following:

  • Data file S1 (Microsoft Excel format). Data file for all figures.